Xiaobo Bo
Impact in
-
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Co-authors
- Yueqi Wang (18 shared papers)Houbao Liu (16 shared papers)Tao Suo (12 shared papers)Jie Wang (11 shared papers)Changcheng Wang (11 shared papers)Xiaoling Ni (10 shared papers)Sheng Shen (10 shared papers)Peizhan Chen (1 shared paper)
- Journals
- Cancer Science (3 papers)Frontiers in Oncology (2 papers)Surgical Endoscopy (2 papers)Oncotarget (2 papers)Orthopaedics & Traumatology Surgery & Research (1 paper)
- Partner nations
- China
In The Last Decade
Xiaobo Bo
23 papers receiving 275 citations
Peers
Comparison fields: 5 of 41
- Cancer Research 80
- Oncology 124
- Surgery 138
- Pulmonary and Respiratory Medicine 99
- Immunology 52
Countries citing papers authored by Xiaobo Bo
This map shows the geographic impact of Xiaobo Bo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobo Bo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobo Bo more than expected).
Fields of papers citing papers by Xiaobo Bo
This network shows the impact of papers produced by Xiaobo Bo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobo Bo. The network helps show where Xiaobo Bo may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaobo Bo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 48 | |
| 2 | MiR-146a suppresses hepatocellular carcinoma by downregulating TRAF6. | 2016 | 33 |
| 3 | 2019 | 25 | |
| 4 | 2018 | 24 | |
| 5 | 2018 | 17 | |
| 6 | 2022 | 17 | |
| 7 | 2019 | 12 | |
| 8 | 2020 | 11 | |
| 9 | 2019 | 10 | |
| 10 | 2020 | 10 | |
| 11 | 2019 | 10 | |
| 12 | 2021 | 10 | |
| 13 | 2021 | 8 | |
| 14 | 2017 | 7 | |
| 15 | 2018 | 6 | |
| 16 | 2017 | 6 | |
| 17 | 2017 | 6 | |
| 18 | 2024 | 5 | |
| 19 | 2022 | 4 | |
| 20 | 2021 | 3 |
About Xiaobo Bo
Xiaobo Bo is a scholar working on Surgery, Oncology, Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 24 papers that have together received 278 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Cancer-related molecular mechanisms research (6 papers), Gallbladder and Bile Duct Disorders (6 papers), MicroRNA in disease regulation (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Pediatric Hepatobiliary Diseases and Treatments (4 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers) and Circular RNAs in diseases (3 papers). The work is most often cited by research in Cancer Research (80 citations), Oncology (124 citations), Surgery (138 citations), Pulmonary and Respiratory Medicine (99 citations) and Immunology (52 citations). Xiaobo Bo has collaborated with scholars based in China. Frequent co-authors include Yueqi Wang, Houbao Liu, Tao Suo, Jie Wang, Changcheng Wang, Xiaoling Ni, Sheng Shen, Peizhan Chen, Zhihui Gao and Han Liu. Their work appears in journals such as Cancer Science, Frontiers in Oncology, Surgical Endoscopy, Oncotarget and Orthopaedics & Traumatology Surgery & Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.